OncoMatch/Clinical Trials/NCT05773040

A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas

Is NCT05773040 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies JV-213 for lymphomas.

Phase 1RecruitingM.D. Anderson Cancer CenterNCT05773040Data as of May 2026

Treatment: JV-213 — To find the highest tolerable dose of JV-213 (a type of autologous CAR T cell therapy) that can be given to patients who have B-cell lymphoma that is relapsed or refractory.

Check if I qualify

Extracted eligibility criteria

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

Min 2 prior lines

Must have received: anti-CD20 antibody — LBCL, FL, marginal zone lymphoma, MCL, Burkitt lymphoma

anti-CD20 antibody

Must have received: anthracycline — LBCL, Burkitt lymphoma

anthracycline therapy

Must have received: alkylating agent — FL, marginal zone lymphoma, MCL

alkylating agent

Must have received: lenalidomide (lenalidomide) — FL, marginal zone lymphoma

lenalidomide therapy

Must have received: BTK inhibitor — marginal zone lymphoma, MCL

BTK inhibitor therapy

Cannot have received: CAR-T cell therapy using non-FMC63 antibody

Any CAR cell therapy using non-FMC63 antibody

Cannot have received: autologous stem cell transplant

Exception: within 6 weeks

Autologous stem cell transplantation within 6 weeks

Cannot have received: allogeneic stem cell transplant

Exception: within 3 months or active graft versus host disease

Allogeneic stem cell transplantation within 3 months or active graft versus host disease

Lab requirements

Blood counts

Absolute neutrophil count of ≥1.0×10^9/L; Absolute lymphocyte count of ≥0.1×10^9/L; Platelet count of ≥75×10^9/L

Kidney function

Creatinine clearance (as estimated by Cockcroft Gault) ≥45 mL/min

Liver function

Serum alanine transaminase (ALT) / aspartate transaminase (AST) ≤5 times the upper limit of normal (ULN); Total bilirubin ≤2 mg/dL, except in patients with Gilbert's syndrome.

Cardiac function

Cardiac ejection fraction ≥45% with no evidence of clinically significant pericardial effusion

Absolute neutrophil count of ≥1.0×10^9/L; Absolute lymphocyte count of ≥0.1×10^9/L; Platelet count of ≥75×10^9/L; Creatinine clearance (as estimated by Cockcroft Gault) ≥45 mL/min; Serum alanine transaminase (ALT) / aspartate transaminase (AST) ≤5 times the upper limit of normal (ULN); Total bilirubin ≤2 mg/dL, except in patients with Gilbert's syndrome; Cardiac ejection fraction ≥45% with no evidence of clinically significant pericardial effusion

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

The University of Texas M D Anderson Cancer Center · Houston, Texas

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify